Raymond Cross, MD
University of Maryland School of Medicine
University of Maryland Medical Center
Baltimore, MD

Raymond Cross, M.D., M.S., AGAF
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Director of the Inflammatory Bowel Disease Program
University of Maryland School of Medicine
Co-Director Digestive Health Center
University of Maryland Medical Center


PERSONAL HISTORY
Raymond K. Cross, Jr., M.D.,M.S., A.G.A.F. is a board certified Gastroenterologist and Associate Professor of Medicine, Division of Gastroenterology and Hepatology, at the University of Maryland School of Medicine in Baltimore, Maryland. He also serves as Director of the Inflammatory Bowel Disease Program at the University of Maryland School of Medicine in Baltimore and is Co-Director of the Digestive Health Center at the University of Maryland Medical Center.

Dr. Cross received his undergraduate degree from Washington and Jefferson College in Washington, Pennsylvania, and his medical degree from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania. He completed his postgraduate training in Internal Medicine at the University of Maryland and Baltimore VA Medical Centers in Baltimore, Maryland, where he was chosen as Chief Resident. He performed his Gastroenterology fellowship also at the University of Maryland and Baltimore VA Medical Centers in Baltimore. In addition, Dr. Cross has obtained a Master of Science degree in Clinical Research at the University of Maryland School of Medicine, Department of Epidemiology and Preventive Medicine, in Baltimore.

RESEARCH INTERESTS
Dr. Cross has published more than 90 articles, reviews, and abstracts focused on inflammatory bowel disease (IBD). His research interests include use of telemedicine systems in IBD, utilization of ionizing radiation in Crohn’s disease, disparities, aging, physician adherence to treatment guidelines, and other outcomes research in IBD. He is also actively involved in clinical trials.

Dr. Cross is currently leading a multicenter, randomized, controlled trial to assess the impact of a telemedicine system in patients with inflammatory bowel disease (TELE-IBD) compared to standard care. The current study funded by the Agency for Healthcare Research and Quality, will evaluate the impact of TELE-IBD on disease activity, quality of life, and utilization of health care resources in patients with ulcerative colitis and Crohn’s disease. The study will be conducted at the University of Maryland, Baltimore, University of Pittsburgh and Vanderbilt University. TELE-IBD will monitor symptoms and side effects for one year. TELE-IBD generates alerts to the health care team if symptoms are active and provides patients with self-action plans based on symptoms. Participants can also report side effects, check body weight, and receive educational messages. Dr. Cross and his research team has studied telemedicine systems previously showing that patients accept the technology and that use of telemedicine improves disease activity, quality of life, and disease knowledge.

CLINICAL SPECIALITY
Inflammatory bowel disease (ulcerative colitis, Crohn's disease, microscopic colitis)

UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE
DIVISION OF GASTROENTEROLOGY AND HEPATOLOGY


Division Head: Jean-Pierre Raufman, MD
The Division of Gastroenterology and Hepatology provides diagnosis and treatment of diseases of the gastrointestinal tract and liver, including gastroesophageal reflux disease, hepatitis and inflammatory bowel disease. The Division has 18 full-time clinical and 5 MD and PhD faculty. With a National Institutes of Health (NIH) T32 Training grant; the novel University of Maryland & NIH GI/Liver Scholars Program; the development of new clinical programs, including one focused on inflammatory bowel disease (IBD); and state-of-the-art treatment facilities, including an endoscopy laboratory with a full range of cutting edge endoscopic diagnostic and therapeutic equipment, our division is poised to become one of the leading GI programs in the country. Our GI training program has also been expanded, improving the quality of scholarly activity pursued by our fellows and increasing the number of fellowships available in this quickly growing field.

 Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.

 Comparative Effectiveness of Anti-TNF Agents for Crohn's Disease in a Tertiary Referral IBD Practice.

 Association of age at diagnosis and Crohn's disease phenotype.

 Psychosocial factors contributing to inflammatory bowel disease activity and health-related quality of life.

 Anti-TNF therapy is associated with decreased imaging and radiation exposure in patients with Crohn's disease.

 Association of age at diagnosis and ulcerative colitis phenotype

 TELEmedicine in Patients with Inflammatory Bowel Disease: TELE-IBD Agency for Healthcare Research and Quality

INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
ELAN PHARMACEUTICALS, INC

 A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn’s Disease
MILLENNIUM PHARMACEUTICALS, INC.

 Differential Response To Microbial Antigens In Older Onset IBD
PROMETHEUS THERAPEUTICS & DIAGNOSTICS

 A Phase III, multicenter, placebo-controlled, randomized, double-blind study to evaluate the safety and efficacy of PROCHYMAL® (ex vivo cultured adult human mesenchymal stem cells) intravenous infusion for the induction of remission in subjects experiencing treatment-refractory moderate-to-severe Crohn’s disease
OSIRIS THERAPEUTICS

 A multicenter, open-label study to evaluate the safety of PROCHYMAL® (remestemcel-L) intravenous infusion in subjects who have received previous remestemcel-L induction treatment for treatment-refractory moderate-to-severe Crohn’s disease
OSIRIS THERAPEUTICS

    Webcasts

    2016-2017 XPERT PERSPECTIVES ON ULCERATIVE COLITIS IN EUROPE (ENGLISH)

    James Lindsay, MD, Peter Irving, MD

    Didactic Lecture

    view details >

    2016-2017 XPERT PERSPECTIVES ON ULCERATIVE COLITIS IN EUROPE (FRENCH)

    Philippe Marteau, MD, Jean-Frederic Colombel, MD

    Didactic Lecture

    view details >

    2016-2017 XPERT PERSPECTIVES ON ULCERATIVE COLITIS IN EUROPE (GERMAN)

    Stefan Schreiber, MD, Daniel C. Baumgart, MD

    Didactic Lecture

    view details >

    2016-2017 XPERT PERSPECTIVES ON ULCERATIVE COLITIS IN EUROPE (SPANISH)

    Yago González Lama, MD, Julian Panes, MD

    Didactic Lecture

    view details >

    Mechanistic Approaches to IBD: Current & Future Management Strategies

    Stephen B. Hanauer, MD (chair), Gary R. Lichtenstein, MD, David G. Binion, MD, William Sandborn, MD, Corey A. Siegel, MD

    Didactic Lecture

    view details >

    Precision Medicine & Novel Therapeutics

    Maria T. Abreu, MD, David G. Binion, MD, Stephen B. Hanauer, MD, Gary R. Lichtenstein, MD, Eduardo V. Loftus JR., MD

    Didactic Lecture

    view details >

    Xpert Perspectives from DDW 2015: Reporting on IBD

    Stephen Hanauer, MD, Maria Abreu, MD, Gary Lichtenstein, MD

    Didactic Lecture

    view details >

    Update on IBD

    Raymond Cross, MD

    Didactic Lecture

    view details >

    Optimizing Therapies for Severe Ulcerative Colitis

    Ellen Scherl, MD

    Didactic Lecture

    view details >

    Epidemiology of IBD

    Edward Loftus, MD

    Didactic Lecture

    view details >

    Xpert Perspectives from DDW - Reporting on IBD

    Maria T. Abreu, MD, Stephen B. Hanauer, MD, Scot Plevy, MD

    Didactic Lecture

    view details >

    eMonograph

    Expert Perspectives in the Management of Inflammatory Bowel Disease (IBD): A Review of Recent Advances

    view details >

    Advances in IBD

    view details >

    Optimizing the Management of Inflammatory Bowel Disease

    view details >

    Webcasts

    Personalizing Approaches to IBD Therapy

    Raymond Cross, MD

    Didactic Lecture

    view details >

    Dinner Meetings

    Content available soon

    Audiocasts

    Content available soon!

    Content available soon!

    © Copyright 2013-2017 GI Health Foundation. All rights reserved.
    This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.